Ocugen, Inc. Files 10-K/A Amendment

TL;DR

<b>Ocugen, Inc. has filed an amendment to its 2023 annual report, providing updated information on its corporate status and filings.</b>

AI Summary

Ocugen, Inc. (OCGN) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. Ocugen, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company's common stock trades on The Nasdaq Stock Market under the symbol OCGN. Ocugen, Inc. is incorporated in Delaware and its principal executive offices are located in Malvern, Pennsylvania. The filing indicates Ocugen is not a well-known seasoned issuer, nor is it required to file reports under Section 13 or 15(d) of the Act. The company has submitted all required reports for the preceding 12 months and has been subject to these filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Ocugen, Inc., this filing contains several important signals. This amendment ensures Ocugen is compliant with SEC reporting requirements, which is crucial for maintaining its listing on The Nasdaq Stock Market. The filing provides transparency to investors regarding the company's regulatory adherence and operational status as of year-end 2023.

Risk Assessment

Risk Level: low — Ocugen, Inc. shows low risk based on this filing. The risk is low as this is a routine amendment to an annual report, indicating compliance rather than new negative developments.

Analyst Insight

Investors should review the specific details within the 10-K/A amendment for any material changes or updates to Ocugen's business and financial reporting.

Key Numbers

• 2023-12-31 — Fiscal Year End (Fiscal year ended December 31, 2023)
• 001-36751 — Commission File Number (SEC file number for Ocugen, Inc.)
• 2024-04-29 — Filing Date (Date the 10-K/A was filed)

Key Players & Entities

• Ocugen, Inc. (company) — Registrant
• The Nasdaq Stock Market (company) — Exchange where common stock is registered
• OCGN (company) — Trading symbol for common stock
• Delaware (company) — State of incorporation
• Malvern, Pennsylvania (company) — Location of principal executive offices
• Securities Exchange Act of 1934 (regulator) — Act under which reports are filed
• Rule 405 (regulator) — Rule related to filing requirements
• Rule 12b-2 (regulator) — Rule defining filer status

FAQ

Industry Context

Ocugen, Inc. operates in the biotechnology sector, focusing on developing therapeutics. As a publicly traded company, it is subject to stringent SEC reporting requirements.

Regulatory Implications

The filing is an amendment to a Form 10-K, which is an annual report required by the Securities and Exchange Commission (SEC) for publicly traded companies.

What Investors Should Do

1. Review the full 10-K/A filing for specific details on any amendments made to the original 10-K.
2. Monitor future SEC filings from Ocugen, Inc. for ongoing operational and financial updates.
3. Verify Ocugen's compliance status with Nasdaq listing requirements.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the annual report
• 2024-04-29: Filing Date — Date of the 10-K/A amendment submission

Year-Over-Year Comparison

This is an amendment (10-K/A) to the previous 10-K filing for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.01 — d 257,328,085 , shares of common stock, $0.01 par value per share, outstanding. Audi
• $1.6 billion — in North America and Mexico, delivering $1.6 billion in revenue before stepping down to purs

Filing Documents

• tm2410371d3_10ka.htm (10-K/A) — 415KB
• tm2410371d3_ex31-1.htm (EX-31.1) — 3KB
• tm2410371d3_ex31-2.htm (EX-31.2) — 3KB
• 0001104659-24-054193.txt (&nbsp;) — 694KB
• ocgn-20231231.xsd (EX-101.SCH) — 3KB
• ocgn-20231231_lab.xml (EX-101.LAB) — 37KB
• ocgn-20231231_pre.xml (EX-101.PRE) — 24KB
• tm2410371d3_10ka_htm.xml (XML) — 6KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Amendment No. 1 on Form 10-K/A contains forward-looking report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are based on assumptions and expectations that may not be realized and involve known and unknown risks, uncertainties and other important factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified in Item 1A entitled "Risk Factors" beginning on page 32 of the Original Annual Report, as well as those discussed in our other filings with the SEC, including our Quarterly Reports on Form 10-Q. As a result, you are cautioned not to unduly rely on these forward-looking statements. We do not assume any obligation to update any forward-looking ii PART III

Directors, Executive Officers, and Corporate Governance

Item 10. Directors, Executive Officers, and Corporate Governance. Directors We have three classes of directors serving staggered three-year terms. Our Board of Directors (our "Board") is presently composed of seven directors. Class I consists of three directors, while Class II and Class III currently consist of two directors each. The terms of our Class I directors will expire at our 2024 annual stockholders meeting. Set forth below is biographical information as of April 29, 2024, for our current directors. There are no family relationships among our executive officers or directors. Name Age Position(s) Held with Ocugen Director Since Class I Directors: Shankar Musunuri, Ph.D., MBA 60 Chairman and Chief Executive Officer 2019 Ramesh Kumar, Ph.D. 68 Director 2019 Junge Zhang, Ph.D. 57 Director 2019 Class II Directors: Uday B. Kompella, Ph.D. 57 Director 2019 Marna C. Whittington, Ph.D. 76 Director 2022 Class III Directors: Kirsten Castillo 51 Director 2020 Prabhavathi Fernandes, Ph.D. 75 Director 2020 Class I Directors Shankar Musunuri, Ph.D ., MBA, has served as Chairman of the Board and as our Chief Executive Officer since going public in September 2019. Dr. Musunuri has served as the Co-Founder and Chairman of Ocugen since its founding in 2013 and has additionally served as Chief Executive Officer since May 2015. Dr. Musunuri is a seasoned industry veteran with about 30+ years of results-driven experience encompassing research and development, operations, and business management including commercial operations in biotechnology as well as pharmaceutical companies. After a long tenure at Pfizer, he founded Nuron Biotech, Inc., which he grew to a commercial company in less than three years, serving as President, CEO and Board member. Dr. Musunuri spent nearly fifteen years at Pfizer, where he held various positions of increasing leadership and responsibility. Dr. Musunuri obtained his PhD in Pharmaceutical Scienc

: Gender Identity

Part I: Gender Identity Directors 3 4*

: Demographic Background

Part II: Demographic Background African American or Black Alaskan Native or Native American Asian 1 4* Hispanic or Latinx Native Hawaiian or Pacific Islander White 2 Two or More Races or Ethnicities LGBTQ+ Did Not Disclose Demographic Background *Includes Dr. Kumar who is not seeking reelection at our 2024 annual meeting of stockholders. Executive Officers The following table sets forth the name, position and age of each of our executive officers as of the date of this report: Name Position Age Shankar Musunuri, Ph.D., MBA Chief Executive Officer 60 Arun Upadhyay, Ph.D. Chief Scientific Officer, Head of Research & Development 42 Huma Qamar, M.D., MPH, CMI Chief Medical Officer 40 Michael Breininger, CPA, MBA, LSSBB Controller, Chief Accounting Officer 41 Shankar Musunuri, Ph.D., MBA – For biographical information for Dr. Musunuri, see "Directors" above. 5 Arun Upadhyay, Ph.D.— has served as our Chief Scientific Officer (CSO) since September 2022 and became an executive officer effective January 1, 2023. Prior to that, Dr. Upadhyay held roles of increasing responsibility since joining us as a Senior/Principal Scientist in February 2017, including serving as our Senior Vice President and Head of Research & Development from December 2021 to September 2022, serving as our Vice President and Head of Research & Development from December 2020 to December 2021, and serving as our Senior Director, Head of Discovery from December 2018 to December 2020. Dr. Upadhyay has over 20 years of experience across the biotechnology industry, academia, and government institutions, focused on discovery research, innovation, and product development. He successfully led multidisciplinary R&D functions including discovery, preclinical and clinical development of mAbs, bispecific, vaccines, and cell and gene therapy-based products. He led cutting-edge molecular and cell biology research contributing to the development of new therapeutics for i

View Full Filing

View this 10-K/A filing on SEC EDGAR